Preclinical assessment of MAGMAS inhibitor as a potential therapy for pediatric medulloblastoma
Our in vitro data showed BT9 antitumor efficacy in DAOY and D425 cell lines, suggesting that BT9 may represent a promising targeted therapeutic in pediatric medulloblastoma. These data, however, need to be further validated in animal models.
Authors
- Zahra Motahari (ORCID: https://orcid.org/0000-0002-0980-3008)
- Malia Bautista (ORCID: https://orcid.org/0000-0002-8589-3631)
- Suresh N. Magge (ORCID: https://orcid.org/0000-0001-8012-1475)
- Daniela A. Bota (ORCID: https://orcid.org/0000-0002-9680-9060)
- Bhaskar C. Das (ORCID: https://orcid.org/0000-0002-5837-027X)
- Christie D. Fowler (ORCID: https://orcid.org/0000-0003-2864-2163)
- Ashley Plant (ORCID: https://orcid.org/0000-0003-4453-6686)
- Clay Hoerig
- Javier Lepe (ORCID: https://orcid.org/0000-0001-8956-6999)
Institutions
- Lurie Children's Hospital (US)
- University of Minnesota (US)
- Children's Hospital of Orange County (US)
- Long Island University (US)
- University of California, Irvine (US)
- University of Michigan (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- PLoS ONE
- Published
- 2024-10-22
- DOI
- https://doi.org/10.1371/journal.pone.0300411
- Primary Topic
- interferon and immune responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pediatric Cancer Research Foundation
- CHOC Foundation
- National Cancer Institute
- National Institute of Neurological Disorders and Stroke
- Chao Family Comprehensive Cancer Center